Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.
Funch D, Mortimer K, Ziyadeh NJ, D Seeger J, Zhou L, Ng E, Ross D, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD. Funch D, et al. Among authors: bosch traberg h. Diabetes Metab Syndr Obes. 2021 Jun 10;14:2619-2629. doi: 10.2147/DMSO.S305496. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 34140791 Free PMC article.
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L, Liu Y, Geng J, Luo Y, Bian F, Lv X, Yang J, Liu J, Peng Y, Li Y, Sun Y, Bosch-Traberg H, Mu Y. Zang L, et al. Diabetes Obes Metab. 2016 Aug;18(8):803-11. doi: 10.1111/dom.12674. Epub 2016 May 20. Diabetes Obes Metab. 2016. PMID: 27060930 Free PMC article. Clinical Trial.
A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
Seino Y, Miyoshi H, Bosch Traberg H, Divyalasya TVS, Nishijima K, Terauchi Y. Seino Y, et al. Among authors: bosch traberg h. J Diabetes Investig. 2022 Aug;13(8):1321-1329. doi: 10.1111/jdi.13789. Epub 2022 Apr 8. J Diabetes Investig. 2022. PMID: 35285173 Free PMC article. Clinical Trial.
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Tack CJ, et al. Among authors: bosch traberg h. Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7. Diabetes Obes Metab. 2019. PMID: 31282028 Free PMC article. Clinical Trial.
Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
Kiyosue A, Seino Y, Nishijima K, Bosch-Traberg H, Kaku K. Kiyosue A, et al. J Diabetes Investig. 2018 Jul;9(4):831-839. doi: 10.1111/jdi.12759. Epub 2017 Nov 24. J Diabetes Investig. 2018. PMID: 28984041 Free PMC article. Clinical Trial.
20 results